FibroBiologics (FBLG) Stock Price, News & Analysis

Company Overview

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Key Stats

• Today's Range: $2.76 to $3.24
• 50-Day Range: $1.86 to $3.89
• 52-Week Range: $1.08 to $55.00
• Volume: 175,875 shs
• Average Volume: 258,713 shs
• Market Capitalization: $98.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

FibroBiologics Stock Analysis - MarketRank™

FibroBiologics scored higher than 44% of companies evaluated by MarketBeat, and ranked 595th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

FibroBiologics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

FibroBiologics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for FibroBiologics are expected to grow in the coming year, from ($0.40) to ($0.36) per share.

Price to Book Value per Share Ratio

FibroBiologics has a P/B Ratio of 70.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.79% of the float of FibroBiologics has been sold short.

Short Interest Ratio / Days to Cover

FibroBiologics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in FibroBiologics has recently increased by 0.43%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

FibroBiologics does not currently pay a dividend.

Dividend Growth

FibroBiologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.79% of the float of FibroBiologics has been sold short.

Short Interest Ratio / Days to Cover

FibroBiologics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in FibroBiologics has recently increased by 0.43%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.50

News Sentiment

FibroBiologics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for FibroBiologics this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for FBLG on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added FibroBiologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, FibroBiologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.80% of the stock of FibroBiologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

FBLG Stock Analysis - Frequently Asked Questions

How have FBLG shares performed this year?

FibroBiologics' stock was trading at $17.75 at the beginning of 2024. Since then, FBLG stock has decreased by 84.2% and is now trading at $2.81.
View the best growth stocks for 2024 here.

When did FibroBiologics IPO?

FibroBiologics (FBLG) raised $144 million in an initial public offering (IPO) on Wednesday, January 31st 2024. The company issued 4,806,226 shares at a price of $30.00 per share.

Who are FibroBiologics' major shareholders?

FibroBiologics' top institutional investors include Charles Schwab Investment Management Inc. (0.20%), Symphony Financial Ltd. Co. (0.07%) and The Manufacturers Life Insurance Company (0.03%).
View institutional ownership trends.

How do I buy shares of FibroBiologics?

Shares of FBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of FibroBiologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that FibroBiologics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Netflix (NFLX).

Company Calendar

• Today: 11/14/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FBLG
• Previous Symbol: NASDAQ:FBLG
• CUSIP: N/A
• CIK: 1958777
• Web: www.fibrobiologics.com
• Phone: 281-671-5150
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +327.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.64
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.04 per share
• Price / Book: 70.25

Miscellaneous

• Outstanding Shares: 35,160,000
• Free Float: 27,846,000
• Market Cap: $98.80 million
• Optionable: N/A
• Beta: N/A